← Back

Wire · opportunities

FDA approves Sanofi's Sarclisa Escena, first anticancer treatment administered via on-body injector

Published

10 July 2026

Topic

opportunities

Sectors

Digital Health

Geography

United States

Source

Read at pharmalive.com

Verified

Fusion42 · 10 July 2026 · Fusion42 review

FDA approves Sarclisa Escena, a subcutaneous formulation of Sanofi's multiple myeloma drug administered via Enable Injections' on-body injector, matching IV efficacy with shorter treatment time and fewer infusion-related reactions.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ The Wire takeaway

If you're building drug-delivery devices, pharma giants now need you to solve the patient experience problem they've ignored for decades. Sanofi just proved that a simpler injector beats IV infusions on efficacy and comfort—that's a commercial template for every high-volume cancer therapy on the market.

Coverage

1 source · 10 Jul 2026

Related on Wire

Topics

Digital Healthdrug-deliveryon-body-injectoroncologydevice-pharmapatient-experience